- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cantargia AB (CANTA)
Cantargia AB stock price live, this page displays ST CANTA stock exchange data. View the CANTA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cantargia AB real time stock price chart below.
What Is the Cantargia AB Stock Price Today?
The Cantargia AB stock price today is 1.81.
What Is the Stock Symbol for Cantargia AB?
The stock symbol for Cantargia AB is "CANTA."
What Stock Exchange Does Cantargia AB Trade On?
Cantargia AB is listed and trades on the Stockholm stock exchange.
Is Cantargia AB a Good Stock to Buy?
Determining whether Cantargia AB, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CANTA quote. (ISIN: SE0006371126)
What Is the Cantargia AB Stock Price Today?
The Cantargia AB stock price today is 1.81.
What Is the Stock Symbol for Cantargia AB?
The stock symbol for Cantargia AB is "CANTA."
What Stock Exchange Does Cantargia AB Trade On?
Cantargia AB is listed and trades on the Stockholm stock exchange.
Is Cantargia AB a Good Stock to Buy?
Determining whether Cantargia AB, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CANTA quote. (ISIN: SE0006371126)
1.81
+0.06(+3.49%)
Real-time Data·
Fair Value
An estimate of a Cantargia AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.68
2.07
52 wk Range
1.68
6.59
Unusual trading volume
1/3
Fair Value
An estimate of a Cantargia AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.682.07
52 wk Range
1.686.59
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CANTA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Cantargia AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
10.00
Upside
+452.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.00
(+452.49% Upside)
Cantargia AB Earnings Call Summary for Q2/2026
- Cantargia posted Q2 2026 net loss of SEK 32.8M (SEK 0.13/share) on minimal revenue of SEK 100K, beating EPS expectations of $0.19 loss.
- Company raised SEK 132M via rights issue and Fenja Capital loan, boosting available funds to SEK 222M and extending cash runway through mid-2028.
- Operating expenses declined 9% YoY in Q2 and 13% in H1 2026, driven by lower R&D spending following CAN10 divestment to Otsuka.
- Stock rose 2.64% to $1.75 but remains near 52-week low of $1.70, down 66% over six months, reflecting investor caution on clinical-stage status.
- Management forecasts continued losses with FY2026 EPS at -$0.08 and revenue of $0.11, rising to $4.03 in FY2027 as development programs advance.
Last Updated: 19/08/2026, 14:56
Read Full TranscriptEarnings
Latest Release
Aug 19, 2026
EPS / Forecast
-0.13 / -0.19
Revenue / Forecast
100K / 2.2M
Compare CANTA to Peers and Sector
Metrics to compare | CANTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCANTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 2.7x | −0.2x | −0.3x | |
PEG Ratio | 0.02 | 0.00 | 0.00 | |
Price/Book | 1.9x | 0.6x | 2.6x | |
Price / LTM Sales | 1.4x | 9.1x | 3.1x | |
Upside (Analyst Target) | - | 120.8% | 48.5% | |
Fair Value Upside | Unlock | 32.4% | 6.3% | Unlock |
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cantargia AB (CANTA) Stock Price Today?
The Cantargia AB stock price today is 1.81 SEK.
What Stock Exchange Does Cantargia AB Trade On?
Cantargia AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Cantargia AB?
The stock symbol for Cantargia AB is "CANTA."
What Is the Cantargia AB Market Cap?
As of today, Cantargia AB market cap is 457.45M SEK.
What Is Cantargia AB's Earnings Per Share (TTM)?
The Cantargia AB EPS (TTM) is 0.64.
When Is the Next Cantargia AB Earnings Date?
Cantargia AB will release its next earnings report on Nov 25, 2026.
From a Technical Analysis Perspective, Is CANTA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Cantargia AB Stock Split?
Cantargia AB has split 2 times.
How Many Employees Does Cantargia AB Have?
Cantargia AB has 22 employees.
What is the current trading status of Cantargia AB (CANTA)?
As of Aug 20, 2026, Cantargia AB (CANTA) is trading at a price of 1.81 SEK, with a previous close of 1.75 SEK. The stock has fluctuated within a day range of 1.68 SEK to 2.07 SEK, while its 52-week range spans from 1.68 SEK to 6.59 SEK.
What Is Cantargia AB (CANTA) Price Target According to Analysts?
The average 12-month price target for Cantargia AB is 10.00 SEK, with a high estimate of 14 SEK and a low estimate of 6 SEK. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +452.49% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.